Phase 2 Breast Cancer Trial, Recruiting NCT06727773 Sponsor: UNC Lineberger Comprehensive Cancer Center Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06727773
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are female
  • You are 18 years old or older at the time of signing up
  • You have been diagnosed with Stage I, II, or III breast cancer
  • Your doctor has recommended chemotherapy as part of your treatment
  • You are signing up before your 3rd chemotherapy treatment session
  • You speak English

Who may not be able to join:

  • You have a known allergy to the drug memantine
  • You have had chemotherapy in the past (before your current treatment plan)
  • You have severe memory or thinking difficulties, as measured by a specific memory test (confirm with trial site)
  • You have had a heart attack in the last 6 months
  • You have heart or bone/joint conditions that would prevent you from exercising
  • You have a severe mental health condition such as schizophrenia or bipolar disorder
  • You currently struggle with alcohol or drug misuse
  • You are unable to swallow capsules
  • You have significantly reduced kidney function (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zev Nakamura, MD, UNC Lineberger Comprehensive Cancer Center

Phone: +1 984-888-9244

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
UNC Lineberger Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
19 August 2025
Est. completion
15 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rates of recruitment; Rates of retention; Rates of adherence; The acceptability of memantine + Get Real and Heel (MEM+EX)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov